Document is current
Any future updates will be listed below
-
Authors
Jansson, Anna K. https://orcid.org/0000-0001-6305-9729
Cohn-Cedermark, Gabriella
Negaard, Helene F. S.
Tandstad, Torgrim
Ståhl, Olof
Hedlund, Annika
Karlsdottir, Åsa
Hellström, Martin
Langberg, Carl W.
Sköld, Camilla https://orcid.org/0000-0001-8212-0003
Haugnes, Hege S.
Glimelius, Ingrid https://orcid.org/0000-0001-6158-3041
-
Funding
Funding for this research was provided by:
Lions Cancer research fund Stiftelsen Onkologiska Kliniken Uppsala
Cancerfonden
- License Information
-
More Information
Article History
Received: 12 September 2025
Revised: 10 November 2025
Accepted: 3 December 2025
First Online: 22 December 2025
Competing interests
: HSH: Advisory board Merck, Presenter for Janssen-Cilag and Bayer. IG: Participate in real-world data collection sponsored by Takeda and participated in educational seminars for Johnson and Johnson, Astra Zeneca, Lilly and Takeda with all reimbursement to the Department. All remaining authors have declared no conflicts of interest.
: The studies were ethically approved by the Regional Board of the Ethical Committee in Stockholm according to the Declaration of Helsinki (ethical permit number 2016/2562-31/2).
: All patients are included in the SWENOTECA quality-of-care registry after informed written information and oral consent. Patients can opt out if they do not want to participate.
